Subacute Sclerosing Panencephalitis (SSPE)
What is Subacute Sclerosing Panencephalitis (SSPE)?
Subacute sclerosing panencephalitis, or SSPE, is a rare brain condition linked to measles infection. It causes inflammation of the brain and spinal cord. This condition develops years after someone has had measles, usually between 6 and 15 years later.
SSPE happens when the measles virus stays in the body after the initial infection. The virus slowly damages brain cells over time. This leads to serious neurological problems that get worse as the condition progresses.
This condition mostly affects children and young adults who had measles before age 2. SSPE is extremely rare, occurring in about 4 to 11 cases per 100,000 measles infections. Vaccination against measles has dramatically reduced SSPE cases in countries with strong immunization programs.
Symptoms
- Behavior changes and personality shifts
- Memory problems and trouble concentrating
- Sudden muscle jerks or spasms
- Loss of coordination and balance
- Vision problems or blindness
- Difficulty speaking or swallowing
- Seizures
- Mental decline and confusion
- Difficulty walking
- Coma in late stages
Symptoms appear gradually and worsen over time. Early signs often include subtle changes in school performance or behavior. Many families initially attribute these changes to other causes before the condition is diagnosed.
Concerned about Subacute Sclerosing Panencephalitis (SSPE)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
SSPE is caused by a persistent measles virus infection in the brain. The condition develops years after the initial measles infection, typically in people who had measles before age 2. The virus remains dormant in the nervous system and eventually causes brain inflammation. Boys are more likely to develop SSPE than girls, with a ratio of about 3 to 1.
Risk factors include getting measles at a very young age, before the immune system is fully developed. People who never received the measles vaccine are at higher risk. Having a weakened immune system may also increase risk. The good news is that measles vaccination nearly eliminates the risk of developing SSPE.
How it's diagnosed
Diagnosing SSPE requires specialized testing beyond routine blood work. Doctors typically start by reviewing medical history, especially any past measles infection. A neurological exam checks for muscle jerks, coordination problems, and mental changes. Brain imaging with MRI can show characteristic patterns of damage.
Blood tests can show elevated measles antibodies, including IgG levels, which are often very high in SSPE. Spinal fluid testing usually reveals high levels of measles antibodies in the fluid around the brain. An electroencephalogram, or EEG, shows distinctive brain wave patterns. Talk to your doctor about specialized testing if SSPE is suspected.
Treatment options
- Antiviral medications like isoprinosine to slow disease progression
- Interferon therapy to support immune function
- Anti-seizure medications to control seizures
- Medications to reduce muscle spasms and jerks
- Physical therapy to maintain mobility as long as possible
- Speech therapy for swallowing and communication difficulties
- Nutritional support when swallowing becomes difficult
- Supportive care to maintain comfort and quality of life
There is no cure for SSPE, and treatment focuses on slowing progression and managing symptoms. Early treatment may help extend life and maintain function longer. Working with a neurologist experienced in rare neurological conditions is essential for the best care approach.
Frequently asked questions
SSPE is caused by the measles virus remaining in the brain after an initial measles infection. The virus stays dormant for years before causing brain inflammation. This typically happens in people who had measles before age 2, when the immune system is still developing. The measles vaccine has made this condition extremely rare.
SSPE usually develops 6 to 15 years after the initial measles infection. The average time is about 7 years. Early measles infection, especially before age 2, increases the risk. The long delay between measles and SSPE symptoms makes it challenging to connect the two conditions initially.
Yes, SSPE is almost entirely preventable through measles vaccination. The MMR vaccine protects against measles and therefore prevents SSPE. Countries with strong vaccination programs have seen SSPE cases drop dramatically. Vaccinating children on schedule is the most effective prevention strategy.
No, SSPE itself is not contagious from person to person. The condition results from a persistent viral infection in one individual's brain. However, measles is highly contagious and spreads easily through respiratory droplets. Preventing measles through vaccination protects both against measles and the later development of SSPE.
Early signs include personality changes, declining school performance, and memory problems. Children may seem more irritable or withdrawn than usual. Clumsiness and mild coordination problems can appear. These subtle changes often progress slowly before more obvious neurological symptoms develop.
Diagnosis involves multiple tests including brain MRI, EEG, and spinal fluid analysis. Blood tests show very high levels of measles antibodies. Spinal fluid also contains elevated measles antibodies. The combination of clinical symptoms, medical history of measles, and test results helps confirm the diagnosis.
Unfortunately, there is no cure for SSPE. Treatment focuses on slowing disease progression and managing symptoms. Some antiviral medications and immune therapies may help extend life and maintain function. Supportive care is essential for maintaining quality of life as the condition progresses.
SSPE is extremely rare, occurring in about 4 to 11 cases per 100,000 measles infections. It affects about 1 in every 10,000 people who get measles. The condition is even rarer in countries with widespread measles vaccination. Boys are affected about three times more often than girls.
The prognosis is poor, as SSPE is a progressive and fatal condition. Most people survive 1 to 3 years after diagnosis, though survival varies. Early treatment may slow progression and extend life. The focus of care shifts to comfort and quality of life as the condition advances.
Children who had measles before age 2 are at highest risk. Boys are more likely to develop SSPE than girls. People with weakened immune systems may also face increased risk. Anyone who had measles and was never vaccinated has some risk, though SSPE remains rare even in these groups.